Pulmonary Disease, Chronic Obstructive Clinical Trial
— CORALOfficial title:
A 12-week Exploratory Study to Characterise the RelatiOnship Between Changes in InflammatoRy Markers, Lung Function, Symptoms And ReLiever Use in Chronic Obstructive Pulmonary Disease Patients (CORAL)
NCT number | NCT04168216 |
Other study ID # | D6930R00002 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 30, 2020 |
Est. completion date | June 22, 2022 |
Verified date | July 2022 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The intention with the study is to have a better understanding of what happens to COPD patients' symptoms, lung function and markers of inflammation over 12 weeks. This information will increase the understanding of COPD and how to design new treatments for COPD in the future.
Status | Completed |
Enrollment | 31 |
Est. completion date | June 22, 2022 |
Est. primary completion date | June 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 130 Years |
Eligibility | Inclusion Criteria for Entry in the Run-in Period: 1. Provision of signed and dated, written ICF prior to any study specific procedures, sampling, and analyses (at Visit 1). 2. Male or female subjects =40 years of age at the time of signing the ICF. 3. A physician diagnosis of COPD and receiving maintenance treatment with a LABA in combination with an ICS, a LAMA, or both (ie, LABA+ICS, LABA+LAMA, or LABA+ICS+LAMA), for at least 3 months prior to Visit 1. 4. Physician-documented prescription and subject-confirmed use of an inhaled short-acting bronchodilator (ß2 agonists or anticholinergics) as rescue medication prior to study. 5. Current or ex-smoker with =10 pack-year history. 6. Post-bronchodilator FEV1/FVC <0.7 recorded in medical history. 7. Blood eosinophils >0.1×109 cells/L. 8. The subject must be able to read, speak, and understand English; and be able to, in the Investigator's judgment, comply with the Study Protocol. 9. Negative pregnancy test (urine) for female subjects of childbearing potential at Visit 1 Incusion Criteria for Entry in the Observational Period: 1. Frequent use of SABA (=200 µg of Ventolin per day, for at least 75% of days in the 3 weeks prior to Visit 2). 2. At least 70% compliance with daily FeNO, spirometry, EXACT, and BCSS during the last 3 weeks prior to Visit 2. 3. Blood eosinophils >0.1×109 cells/L at Visit 2. 4. Negative pregnancy test (urine) for female subjects of childbearing potential at Visit 2. Exclusion Criteria: 1. As judged by the Investigator, any evidence of drug/substance abuse which would pose a risk to subject safety, interfere with the conduct of study, have an impact on the study results, or affect the subject's ability to participate in the study. 2. Concurrent Respiratory Disease: Presence of a known pre-existing, clinically important lung condition other than COPD. 3. Concurrent diagnosis of asthma (subjects with a history of asthma may be included). 4. Any disease currently treated with chronic oral/systemic corticosteroids. 5. Subjects with a history/treatment of malignancy, and which in the Investigator's opinion could compromise the safety of the subject. 6. Other Concurrent Medical Conditions: Subjects who have known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological or any other system abnormalities that are uncontrolled with standard treatment. 7. Subjects currently treated with eosinophil-depleting medications (ie, mepolizumab, benralizumab), or who have been treated within 5.5 half-lives of eosinophil-depleting medications. 8. Subjects who have had a COPD exacerbation requiring oral corticosteroids and/or antibiotics in the last 30 days before the run-in period. Subjects will be able to be re-screened 30 days following an exacerbation. 9. Participation in another clinical study with any marketed or investigational biologic drug within 4 months or 5 half-lives (whichever is longer) prior to Visit 1. 10. Participation in another clinical study with a non-biologic investigational product or new formulation of a marketed non-biologic drug during the last 30 days prior to Visit 1 that, in the opinion of the Investigator, could impact the results of the current study. 11. Subjects with a known hypersensitivity to the treatment or any of the excipients of Duaklir and Ventolin. 12. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). 13. Judgment by the Investigator that the subject should not participate in the study if the subject is unlikely to complete the observational period (eg, literacy, substance abuse, life-threatening comorbidity). 14. Previous entry into the observation period in the present study. 15. For women only - currently pregnant (confirmed with positive pregnancy test), breast-feeding or planned pregnancy during the study. Women of childbearing potential not using acceptable contraceptive measures, as judged by the Investigator. 16. As judged by the Investigator, planned hospitalisation/vacation during the study that interferes with study assessments. - |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Research Site | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca | University of Oxford |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory Biomarker data will be plotted for each subject over the 12 weeks of the study / around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Inflammation: Biomarkers from expectorate sputum samples (weekly) Biomarkers from nasal absorption samples (weekly) Plasma and serum exploratory biomarkers (fortnightly) |
12 weeks | |
Other | Exploratory Night time symptoms data will be plotted for each subject over the 12 weeks of the study / around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Symptoms: Night-time symptoms (passive monitoring, daily) |
12 weeks | |
Primary | Inflammation data will be plotted for each subject over the 12 weeks of the study to provide an understanding of the temporal dynamics of the data. | Inflammation: FeNO (daily) Blood eosinophils, CRP, and EDN (fortnightly) Sputum eosinophils and neutrophils (weekly) |
12 weeks | |
Primary | Lung function data will be plotted for each subject over the 12 weeks of the study to provide an understanding of the temporal dynamics of the data. | Lung function: FEV1, PEF, Oscillometry (daily) |
12 weeks | |
Primary | Symptoms data (BCSS) will be plotted for each subject over the 12 weeks of the study to provide an understanding of the temporal dynamics of the data. | Symptoms: BCSS (daily) |
12 weeks | |
Primary | Symptoms data (E-RS) will be plotted for each subject over the 12 weeks of the study to provide an understanding of the temporal dynamics of the data. | Symptoms: E-RS (daily) |
12 weeks | |
Primary | Symptoms data (VAS-COPD) will be plotted for each subject over the 12 weeks of the study to provide an understanding of the temporal dynamics of the data. | Symptoms: VAS-COPD (daily) |
12 weeks | |
Primary | Symptoms data (SGRQ) will be plotted for each subject over the 12 weeks of the study to provide an understanding of the temporal dynamics of the data. | Symptoms: SGRQ (fortnightly) |
12 weeks | |
Primary | Symptoms data (CAT) will be plotted for each subject over the 12 weeks of the study to provide an understanding of the temporal dynamics of the data. | Symptoms: CAT (fortnightly) |
12 weeks | |
Primary | Reliever use data will be plotted for each subject over the 12 weeks of the study to provide an understanding of the temporal dynamics of the data. | Reliever use: Ventolin® use (daily) |
12 weeks | |
Secondary | Inflammation data will be plotted for a subject around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Inflammation: FeNO (daily) Blood eosinophils, CRP, and EDN (fortnightly) Sputum eosinophils and neutrophils (weekly) |
12 weeks | |
Secondary | Lung function data will be plotted for a subject around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Lung function: FEV1, PEF, Oscillometry (daily) |
12 weeks | |
Secondary | Symptoms data (BCSS) will be plotted for a subject around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Symptoms: BCSS (daily) |
12 weeks | |
Secondary | Symptoms data (E-RS) will be plotted for a subject around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Symptoms: E-RS (daily) |
12 weeks | |
Secondary | Symptoms data (VAS-COPD) will be plotted for a subject around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Symptoms: VAS-COPD (daily) |
12 weeks | |
Secondary | Symptoms data (SGRQ) will be plotted for a subject around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Symptoms: SGRQ (fortnightly) |
12 weeks | |
Secondary | Symptoms data (CAT) will be plotted for a subject around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Symptoms: CAT (fortnightly) |
12 weeks | |
Secondary | Reliever use data will be plotted for a subject around a COPD worsening event to provide an understanding of the temporal dynamics of the data. | Reliever use: Ventolin® use (daily) |
12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|